Full Text:   <1833>

Summary:  <1428>

CLC number: R742.1

On-line Access: 2015-07-03

Received: 2015-01-20

Revision Accepted: 2015-06-05

Crosschecked: 2015-06-16

Cited: 7

Clicked: 3579

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Ying Zhang

http://orcid.org/0000-0001-9788-6685

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2015 Vol.16 No.7 P.611-621

http://doi.org/10.1631/jzus.B1500021


Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis


Author(s):  Ying Zhang, Yu-xin Zheng, Jun-ming Zhu, Jian-min Zhang, Zhe Zheng

Affiliation(s):  Neuroscience Care Unit, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; more

Corresponding email(s):   daqingzy1978@163.com, zhengzhe19821982@gmail.com

Key Words:  Antiepileptic drugs, Bone mineral density, Bone metabolism, Children, Meta-analysis


Ying Zhang, Yu-xin Zheng, Jun-ming Zhu, Jian-min Zhang, Zhe Zheng. Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis[J]. Journal of Zhejiang University Science B, 2015, 16(7): 611-621.

@article{title="Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis",
author="Ying Zhang, Yu-xin Zheng, Jun-ming Zhu, Jian-min Zhang, Zhe Zheng",
journal="Journal of Zhejiang University Science B",
volume="16",
number="7",
pages="611-621",
year="2015",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1500021"
}

%0 Journal Article
%T Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis
%A Ying Zhang
%A Yu-xin Zheng
%A Jun-ming Zhu
%A Jian-min Zhang
%A Zhe Zheng
%J Journal of Zhejiang University SCIENCE B
%V 16
%N 7
%P 611-621
%@ 1673-1581
%D 2015
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1500021

TY - JOUR
T1 - Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis
A1 - Ying Zhang
A1 - Yu-xin Zheng
A1 - Jun-ming Zhu
A1 - Jian-min Zhang
A1 - Zhe Zheng
J0 - Journal of Zhejiang University Science B
VL - 16
IS - 7
SP - 611
EP - 621
%@ 1673-1581
Y1 - 2015
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1500021


Abstract: 
Objective: The aim of our meta-analysis was to assess the effects of antiepileptic drugs on bone mineral density and bone metabolism in epileptic children. Methods: Searches of PubMed and Web of Science were undertaken to identify studies evaluating the association between antiepileptic drugs and bone mineral density and bone metabolism. Results: A total of 22 studies with 1492 subjects were included in our research. We identified: (1) a reduction in bone mineral density at lumbar spine (standardized mean difference (SMD)=−0.30, 95% confidence interval (CI) [−0.61, −0.05]), trochanter (mean difference (MD)=−0.07, 95% CI [−0.10, −0.05]), femoral neck (MD=−0.05, 95% CI [−0.09, −0.02]), and total body bone mineral density (MD=−0.33, 95% CI [−0.51, −0.15]); (2) a reduction in 25-hydroxyvitamin D (MD=−3.37, 95% CI [−5.94, −0.80]) and an increase in serum alkaline phosphatase (SMD=0.71, 95% CI [0.38, 1.05]); (3) no significant changes in serum parathyroid hormone, calcium, or phosphorus. Conclusions: Our meta-analysis suggests that treatment with antiepileptic drugs may be associated with decreased bone mineral density in epileptic children.

抗癫痫药物影响儿童骨矿物质密度及骨代谢的荟萃分析

目的:癫痫是神经系统常见病,半数以上患者儿童时期便发病,癫痫病患者常需终身服用抗癫痫药。研究表明,长期服用抗癫痫药物会影响骨代谢,加速骨矿物质的丢失,导致骨质疏松。但是,每种抗癫痫药物的具体作用还不清楚。作为典型的肝酶诱导剂的抗癫痫药物,卡马西平已经公认有降低骨密度的作用,但是作为非肝酶诱导剂的丙戊酸钠,还没有定论。在新型抗癫痫药物中,奥卡西平、托吡酯和拉莫三嗪等对骨密度似乎没有影响,但目前相关的研究很少,各研究所得结果也不一致。本研究拟通过荟萃分析评估抗癫痫药对癫痫病儿童骨密度和骨代谢的影响。
创新点:目前已有荟萃分析评估抗癫痫药对成人骨密度的影响,但尚无研究分析抗癫痫药对儿童的影响。
方法:检索PubMed和Web of Science数据库中评估抗癫痫药与儿童骨密度及骨代谢关系的临床试验。入选标准为:(1)至少包括一项骨代谢的标志物;(2)骨密度用双能×线吸收计量法计算;(3)研究结果包括平均的骨密度和骨密度的标准差;(4)年龄小于18岁;(5)患者采用单药或多药治疗;(6)具有健康对照组;(7)必须是观察性研究或随机对照研究。采用固定效应模型和随机效应模型对22篇文献的1492例患者中的骨密度及骨代谢资料进行荟萃分析,结果用加权均数差(WMD)或标准均数差(SMD)进行评估。
结论:共22篇文献符合纳入标准,共计1492例患者。荟萃分析的结果显示,抗癫痫药物的使用可以引起儿童:(1)腰椎、转子、股骨颈的骨密度和全身骨密度的下降;(2)维生素D下降和血清碱性磷酸酶的上升;(3)甲状旁腺激素、钙和磷没有显著改变。荟萃分析的结果表明,抗癫痫药的使用可能和癫痫病患儿骨密度降低相关。

关键词:抗癫痫药;骨密度;骨代谢;荟萃分析

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Akin, R., Okutan, V., Sarici U., et al., 1998. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr. Neurol., 19(2):129-131.

[2]Babacan, O., Karaoglu, A., Vurucu, S., et al., 2012. May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism? J. Clin. Neurol., 8(1):65-68.

[3]Babayigit, A., Dirik, E., Bober, E., et al., 2006. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr. Neurol., 35(3):177-181.

[4]Baer, M.T., Kozlowski, B.W., Blyler, E.M., et al., 1997. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am. J. Clin. Nutr., 65(4):1042-1051.

[5]Begley, C.E., Famulari, M., Annegers, J.F., et al., 2000. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia, 41(3):342-351.

[6]Bergqvist, A.G.C., Schall, J.I., Stallings, V.A., 2007. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia, 48(1):66-71.

[7]Cerveny, L., Svecova, L., Anzenbacherova, E., et al., 2007. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos., 35(7):1032-1041.

[8]Chung, S., Ahn, C., 1994. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev., 16(5):382-385.

[9]Dent, C.E., Richens, A., Rowe, D.J., et al., 1970. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br. Med. J., 4(5727):69-72.

[10]Dimić, M., Dimić, A., Milosević, Z., et al., 2013. Bone mineral density in children with long-term antiepileptic therapy. Srp. Arh. Celok. Lek., 141(5-6):329-332 (in Serbian).

[11]Ecevit, C., Aydoğan, A., Kavakli, T., et al., 2004. Effect of carbamazepine and valproate on bone mineral density. Pediatr. Neurol., 31(4):279-282.

[12]El-Hajj Fuleihan, G., Dib, L., Yamout, B., et al., 2008. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone, 43(1):149-155.

[13]Erbayat Altay, E., Serdaroglu, A., Tumer, L., et al., 2000. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J. Pediatr. Endocrinol. Metab., 13(7):933-939.

[14]Feldkamp, J., Becker, A., Witte, O.W., et al., 2000. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp. Clin. Endocrinol. Diabetes, 108(1):37-43.

[15]Gniatkowska-Nowakowska, A., 2010. Fractures in epilepsy children. Seizure, 19(6):324-325.

[16]Hannan, M.T., Litman, H.J., Araujo, A.B., et al., 2008. Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men. J. Clin. Endocrinol. Metab., 93(1):40-46.

[17]Kafali, G., Erselcan, T., Tanzer, F., 1999. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin. Pediatr., 38(2):93-98.

[18]Karceski, S.C., 2007. Seizure medications and their side effects. Neurology, 69(22):E27-E29.

[19]Keck, E., Gollnick, B., Reinhardt, D., et al., 1982. Calcium metabolism and vitamin D metabolite levels in children receiving anticonvulsant drugs. Eur. J. Pediatr., 139(1):52-55.

[20]Kumandas, S., Koklu, E., Gümüs, H., et al., 2006. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J. Pediatr. Endocrinol. Metab., 19(4):529-534.

[21]Lee, R.H., Lyles, K.W., Colón-Emeric, C., 2010. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am. J. Geriatr. Pharmacother., 8(1):34-46.

[22]Liberati, A., Altman, D.G., Tetzlaff, J., et al., 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med., 151(4):W65-W94.

[23]Meier, C., Kraenzlin, M.E., 2011. Antiepileptics and bone health. Ther. Adv. Musculoskelet. Dis., 3(5):235-243.

[24]Mikati, M.A., Dib, L., Yamout, B., et al., 2006. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology, 67(11):2005-2014.

[25]Nettekoven, S., Ströhle, A., Trunz, B., et al., 2008. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur. J. Pediatr., 167(12):1369-1377.

[26]Nicolaidou, P., Georgouli, H., Kotsalis, H., et al., 2006. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J. Child. Neurol., 21(3):205-209.

[27]Oner, N., Kaya, M., Karasalihoglu, S., et al., 2004. Bone mineral metabolism changes in epileptic children receiving valproic acid. J. Paediatr. Child Health, 40(8):470-473.

[28]Pack, A.M., Morrell, M.J., 2001. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs, 15(8):633-642.

[29]Pack, A.M., Morrell, M.J., Randall, A., et al., 2008. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology, 70(18):1586-1593.

[30]Petty, S.J., Paton, L.M., O'Brien, T.J., et al., 2005. Effect of antiepileptic medication on bone mineral measures. Neurology, 65(9):1358-1365.

[31]Rauchenzauner, M., Griesmacher, A., Tatarczyk, T., et al., 2010. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev. Med. Child Neurol., 52(3):283-288.

[32]Razazizan, N., Mirmoeini, M., Daeichin, S., et al., 2013. Comparison of 25-hydroxy vitamin D, calcium and alkaline phosphatase levels in epileptic and non-epileptic children. Acta. Neurol. Taiwan, 22(3):112-116.

[33]Reid, I.R., Bolland, M.J., Grey, A., 2014. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet, 383(9912):146-155.

[34]Salimipour, H., Kazerooni, S., Seyedabadi, M., et al., 2013. Antiepileptic treatment is associated with bone loss: difference in drug type and region of interest. J. Nucl. Med. Technol., 41(3):208-211.

[35]Shellhaas, R.A., Joshi, S.M., 2010. Vitamin D and bone health among children with epilepsy. Pediatr. Neurol., 42(6):385-393.

[36]Sheth, R.D., Hermann, B.P., 2008. Bone in idiopathic and symptomatic epilepsy. Epilepsy Res., 78(1):71-76.

[37]Sheth, R.D., Wesolowski, C.A., Jacob, J.C., et al., 1995. Effect of carbamazepine and valproate on bone mineral density. J. Pediatr., 127(2):256-262.

[38]Sheth, R.D., Binkley, N., Hermann, B.P., 2008. Progressive bone deficit in epilepsy. Neurology, 70(3):170-176.

[39]Souverein, P.C., Webb, D.J., Petri, H., et al., 2005. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia, 46(2):304-310.

[40]Turan, M.I., Cayir, A., Ozden, O., et al., 2014. An examination of the mutual effects of valproic acid, carbamazepine, and phenobarbital on 25-hydroxyvitamin D levels and thyroid function tests. Neuropediatrics, 45(1):16-21.

[41]Verrotti, A., Greco, R., Latini, G., et al., 2002. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia, 43(12):1488-1492.

[42]Verrotti, A., Coppola, G., Parisi, P., et al., 2010. Bone and calcium metabolism and antiepileptic drugs. Clin. Neurol. Neurosurg., 112(1):1-10.

[43]Vestergaard, P., 2005. Epilepsy, osteoporosis and fracture risk—a meta-analysis. Acta Neurol. Scand., 112(5):277-286.

[44]Voudris, K., Moustaki, M., Zeis, P.M., et al., 2002. Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy. Seizure, 11(6):377-380.

[45]Voudris, K.A., Attilakos, A., Katsarou, E., et al., 2005. Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes. J. Child. Neurol., 20(6):513-516.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE